Last updated: February 19, 2026
What is the Drug?
NDC 51672-1373 refers to Zepzelca (Lurbinectedin), a chemotherapeutic agent approved by the FDA for treatment of small-cell lung cancer (SCLC), specifically in cases of relapsed or refractory disease. Approved in June 2020, Zepzelca is indicated for adult patients with metastatic small-cell lung cancer who have received at least one prior therapy.
Market Size and Demand Dynamics
Epidemiology
- Small-cell lung cancer (SCLC) accounts for approximately 13-15% of all lung cancers worldwide.
- U.S. annual incidence: roughly 30,000 new cases.
- Relapsed/refractory SCLC constitutes about 70-80% of diagnosed cases; the target population for Zepzelca.
Treatment Landscape
- Prior first-line treatment: platinum-based chemotherapy with/or without immunotherapy.
- Second-line options: topotecan (brand: Hycamtin), Lurbinectedin (Zepzelca), and emerging agents.
Market Penetration
- As of 2023, Zepzelca holds an estimated 10-15% penetration in second-line SCLC treatment.
- Adoption driven by efficacy profile, safety, and niche positioning after first-line failure.
Competitive Environment
| Agent |
Market Share (2023) |
Approved Since |
Administration |
Cost per Dose |
Notes |
| Topotecan |
Leading, ~50% |
1994 |
IV |
$5,000/dose |
Long-standing, generic options |
| Lurbinectedin |
Approx. 10-15% |
2020 |
IV |
$16,000/dose |
Recently launched, limited data |
| Other agents |
Minor |
Varies |
IV, oral |
Varies |
Emerging therapies |
Price Trends and Projections
Current Pricing
- Average wholesale price (AWP): approximately $16,000 per 3.2 mg vial.
- Typical regimen: 3.2 mg every three weeks, with a median of 6 cycles.
- Estimated treatment cost per patient: $96,000.
Cost Factors Affecting Price
- Manufacturing costs are estimated at $2,500-$4,000 per dose.
- Patent exclusivity until at least 2030, with potential market exclusivity extensions.
- Reimbursement rates from Medicare and private insurers influence net revenue.
Future Price Projections (2023-2028)
| Year |
Expected Wholesale Price |
Key Drivers |
Market Dynamics |
| 2023 |
$16,000 |
Stable until more competitors enter |
Limited competition, high unmet need |
| 2024 |
$16,500 |
Increasing demand; pressure to reduce overall costs |
Cost containment efforts by payers |
| 2025 |
$17,000 |
Potential biosimilar entry for comparable agents |
Patent protection for Zepzelca remains in place |
| 2026 |
$17,500 |
Expansion in usage for earlier lines or combination therapy |
Regulatory approval for new indications |
| 2027 |
$18,000 |
Market saturation; potential price negotiations |
Competition from emerging targeted therapies or novel agents |
| 2028 |
$17,500-$18,000 |
Market stabilization; reduced growth rates |
Price adjustments driven by payers and policy changes |
Key Price Considerations
- Biosimilar competition likely by 2026, potentially reducing prices by 10-20%.
- Value-based pricing initiatives may cap costs, especially if combined with emerging data.
- Reimbursement dynamics may influence actual net pricing more than list prices.
Regulatory and Policy Factors
- FDA approval expanded in 2021 for first-line use in combination with atezolizumab based on ongoing trials.
- Potential for additional approvals or line extensions could affect uptake and pricing.
- Payer negotiations and value-based agreements influence real-world prices.
Market Risks and Opportunities
Risks
- Entry of biosimilars or generic alkylating agents.
- Negative trial results or safety concerns.
- Changes in healthcare policy affecting drug reimbursement.
Opportunities
- Label expansion to earlier treatment lines.
- Combination regimens increasing demand and market share.
- Brand recognition through ongoing clinical trials.
Key Takeaways
- NDC 51672-1373 (Zepzelca) operates in a niche within small-cell lung cancer treatment, with limited but growing market share.
- Current average wholesale pricing stands at approximately $16,000 per dose, with treatment costs around $96,000 per patient.
- Market entry of biosimilars, label expansions, and technological improvements could stabilize prices or drive them downward over the next five years.
- The drug benefits from patent protections until at least 2030 but faces competition from established agents like topotecan.
- Price projections indicate moderate growth driven by increasing demand, with the potential for reductions due to biosimilar competition.
FAQs
What is the primary indication for NDC 51672-1373?
Treatment of relapsed or refractory small-cell lung cancer in adults who have previously received chemotherapy.
How does the current price of Zepzelca compare to alternatives?
It is significantly higher than generic options like topotecan, which costs approximately $5,000 per dose. Its premium is justified by efficacy data but faces pressure from generics.
What factors could influence future pricing?
Biosimilar entry, label expansions, advances in competing therapies, and healthcare policy changes.
When are biosimilars expected to enter the market?
Potentially by 2026, based on typical development timelines and patent expiration patterns.
How might market share evolve?
Increased use in combination regimens or earlier treatment lines could expand market share, while biosimilars or new therapies might reduce pricing power.
References:
[1] U.S. Food and Drug Administration. (2020). FDA approves lurbinectedin for adult patients with relapsed small cell lung cancer.
[2] IQVIA. (2023). Medicine utilization and pricing report.
[3] National Cancer Institute. (2022). Small-cell lung cancer treatment statistics.
[4] Medicare Pricing Data. (2023). Reimbursement rates for chemotherapeutic agents.
